Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration of CT-L03 in Healthy Volunteers
← catalyst calendarSponsored by Celltrion (industry) · 068270.KS — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
49actual
Sites
1
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-18 | actual | When the study began enrolling |
| Primary completion | 2025-10-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-23 | actual | The whole study's end, after follow-up |
| First posted | 2025-09-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Type 2 Diabetes Mellitus (T2DM)
Interventions
- Drug: L03RD1
- Drug: L03RD2
- Drug: CT-L03
Primary outcomes
what the primary-completion date above is the date OFAUCt
measured Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
Cmax
measured Pre-dose, 0.33, 0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 12, 16, 24, 48, 72 and 96 hours
Permalink · 068270.KS's whole pipeline · Catalyst calendar · Every registered study · What changed